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Background: When new pharmaceutical products appear on the market, physicians need to know whether they
are likely to be useful in their practices. Physicians currently obtain most of their information about the market
release and properties of new drugs from pharmaceutical industry representatives. However, the official information
contained in the summary of product characteristics (SPCs) and evaluation reports from health agencies, provide a
more complete view of the potential value of new drugs, although they can be long and difficult to read. The main
objective of this work was to design a prototype computer program to facilitate the objective appraisal of the
potential value of a new pharmaceutical product by physicians. This prototype is based on the modeling of
pharmaceutical innovations described in a previous paper.
Methods: The interface was designed to allow physicians to develop a rapid understanding of the value of a new
drug for their practices. We selected five new pharmaceutical products, to illustrate the function of this prototype.
We considered only the texts supplied by national or international drug agencies at the time of market release. The
perceived usability of the prototype was evaluated qualitatively, except for the System Usability Scale (SUS) score
evaluation, by 10 physicians differing in age and medical background.
Results: The display is based on the various axes of the conceptual model of pharmaceutical innovations. The user
can select three levels of detail when consulting this information (highly synthetic, synthetic and detailed). Tables
provide a comparison of the properties of the new pharmaceutical product with those of existing drugs, if available
for the same indication, in terms of efficacy, safety and ease of use.
The interface was highly appreciated by evaluators, who found it easy to understand and suggested no other
additions of important, internationally valid information. The mean System Usability Scale score for the 10
physicians was 82, corresponding to a “good” user interface.
Conclusions: This work led us to propose the selection, grouping, and mode of presentation for various types of
knowledge on pharmaceutical innovations in a way that was appreciated by evaluators. It provides physicians with
readily accessible objective information about new drugs.Background
When new pharmaceutical products are released onto the
market, physicians need to determine whether they are
likely to be useful in their own practices. Physicians cur-
rently obtain most of their information about the market
release and properties of new drugs from pharmaceutical
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strong influence on the prescription practices of general
practitioners (GPs) [2,3]. This information generally gives
a very positive image of the products concerned [4,5]. Un-
fortunately, various studies [6] have shown that the quality
of prescription by GPs is negatively correlated with the
frequency of visits from representatives of the pharma-
ceutical industry.
Physicians need to develop their own ideas about the
value of new drugs. They may consider that a new drug
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curious about the potential value of a new drug of for
their practice, but their decision to reject or accept it
will be based on its efficacy and safety.
Scientific papers presenting the results of clinical trials
and evaluation reports produced by health agencies are
publicly available via the Internet and can help doctors
to determine the efficacy of a new drug, but they are
time-consuming to read.
Physicians can compare the safety aspects of new
drugs with those of other drugs already used for the
same indication, by analyzing the content of the sum-
mary of product characteristics (SPC) and drug mono-
graphs to check for contraindications, interactions,
precautions, warnings and adverse reactions. However, it
would be unrealistic to expect physicians to carry out
such a task, which would be both difficult and time-
consuming.
Various attempts have been made to increase the un-
derstanding and use of safety information about drugs.
Commercial editors of drug databases have developed
systems for comparing the safety aspects of the SPCs of
two drugs, by contrasting the contraindications or side
effects of the drugs compared, for example. However,
the information provided is still time-consuming to read
and would benefit from synthetic, and possibly graphical
approaches to decrease the cognitive burden of the com-
parison of textual elements of this kind.
An iconic language was developed in a previous study
[7], for the presentation of medical concepts. This lan-
guage has been applied to the presentation of drug con-
traindications and interactions and has been shown to
make the reading of drug monographs more rapid [8].
Software has been created to improve medication
safety in an emergency department, by enhancing the in-
tegration and presentation of safety information for drug
treatments [9]. This decision support system alerts the
user to potential drug interactions and contraindications.
It is a four-step system, with the last step providing ac-
cess to the most detailed information about the drug. It
was developed to decrease significantly the time required
for doctors to obtain documentation about drugs.
Drug fact boxes, a concept recently developed in the
USA, provide valuable synthetic and comparative infor-
mation about the efficacy and safety of drugs. These
documents have been shown to be effective for patient
information [10,11], but are not detailed enough for
physicians. The comparative information is easy to read,
but succinct. Several topics of importance to the phys-
ician [12] are not considered: the type of originality of
the new drug (e.g. mechanism of action, pharmacother-
apeutic group, galenic innovation) and its ease of use
(e.g. existence of an antidote, need for laboratory tests
during treatment).A tool providing physicians with comparative drug in-
formation would be useful, if it provided both synthetic
and detailed information about new drugs, comparing
them with existing drugs for the same indication. Such a
tool could be extended to cover all drugs, both new and
older, but the development of such a tool might be diffi-
cult, time-consuming and costly, because there are many
commercial products, evaluated at different times, some
as long as 40 years ago, with different protocols and
evaluation criteria.
Our main objective in this study was to design a
prototype computer program to assist physicians in their
evaluation of the potential value of new pharmaceutical
products. This tool was designed to be used periodically
by physicians for training, but not in front of patients.
This computer program was based on a previously de-
scribed model [12], in which we identified the key items of
information required for a fair appraisal of pharmaceutical
innovations. We modeled this information, by grouping
these items into three categories of information: (i) the
medical context of use of the new pharmaceutical product,
including the therapeutic arsenal for the same indication
(the therapeutic arsenal is the entire set of drugs that may
be prescribed for a given indication); (ii) the description of
the pharmaceutical characteristics of the innovation in
terms of its chemical, pharmacological and galenic proper-
ties; (iii) the expected impact of the new drug in terms of
efficacy, safety and ease of use for the patient and the
physician, as determined by comparison with other prod-
ucts for the same indication.
The interface was designed to enable the physician to
develop a rapid understanding of the value of a new
drug for his or her practice and should encourage physi-
cians to go into greater detail and to analyze the avail-
able information for drugs identified as real innovations.
We will first present our methodological approach,
which includes several levels of information synthesis,
carried out as objectively as possible. We will then de-
scribe the design of the software and present the princi-
pal results for its qualitative evaluation.
Methods
Overall approach
In a previous study [12], we developed a model illustrat-
ing the basic features of a new pharmaceutical product.
This model was constructed from the knowledge con-
tained in the evaluation reports of the French National
Authority for Health (HAS) and the SPCs of 40 drugs
approved from 1 January 2008 to 1 January 2011. An ini-
tial set of innovation axes was selected by two authors.
The model was then gradually developed through the
reading of evaluation reports and of the SPCs of new
drugs and of the drugs to which these new drugs were
compared in the evaluation report for the items relating
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available therapeutic arsenal for items assessing novelty.
We described the context of use of a new drug, its type
of novelty, and elements influencing the impact (e.g. effi-
cacy, safety, ease of use) of the new manufactured prod-
uct with respect to a comparator. We follow the same
separation of information in the development of the new
drug presentation.
The interface must initially provide the physician with
a first level of information granularity. An intermediate
level should then provide more information, but should
remain synthetic in nature, with elements that can be
read rapidly. The third level of granularity should involve
the display of more detailed information, including, in
particular, excerpts of the evaluation report [13] and
SPC. Recommendations have been made concerning the
use of multiple views in information visualization, to il-
lustrate different levels of abstraction [14].
We therefore created a first interface element, to
provide a global description of the innovative features
of any pharmaceutical product. We then decided to de-
velop specific interfaces providing detailed information
about each of the axes of innovation in the model pre-
sented in our previous study [12]. The interface is
represented with stable elements, to avoid the need
for learning.
Choice of the type of graphical representation of
information
We chose to use two-dimensional arrays for visualization
in several places. These tables are highly suitable for com-
parisons of the properties of two drugs. Concepts are sepa-
rated by changes in line thickness in the table. The table is
thus divided into two parts, making it possible to differenti-
ate between different types of data, such as quantitative
data from clinical trials and the conclusions of experts.
We reduced the volume of text in the tables through the
use of graphical representation in the form of pictograms.
We introduced modes of interaction with the user,
providing physicians with easy access to more detailed
sections from the global view. We ensured that the
interface of the application did not appear overloaded,
by displaying the value of cells through mouseovers (for
example: for side effects, green indicates that the side
effect was not reported).
Identification of the corpus of information concerning the
drug in the used sources
For data input into our system, we used the SPCs and
evaluation reports of the French National Authority for
Health (HAS). SPC information was extracted from the
Claude Bernard database [15], which uses reference ter-
minologies, such as MedDRA, ATC, IDC10, to index in-
formation contained in free text.The characteristics of novelty of the drug were deter-
mined by considering all the drugs with the same indica-
tion described in the report of the French National
Authority for Health (HAS) [13]. These drugs are pre-
sented by pharmacotherapeutic group in the report.
For each of these drugs, we used the SPC information
available from the Claude Bernard database, including,
in particular, the paragraphs concerning composition,
pharmacodynamics, therapeutic indications, dosage,
route of administration, technical and regulatory data
(approval date, price, etc.).
We selected the comparator from the clinical trials de-
scribed in the evaluation report of the French National
Authority for Health (HAS). For a new drug for a given
indication, in the best of cases, there is a comparator
with the active ingredient; in most cases, the new drug is
compared to placebo.
We used the results of clinical trials, based on the pri-
mary endpoints mentioned in the evaluation report [13],
to describe the impact of the drug in terms of its effi-
cacy. For description of the impact of the drug in terms
of safety, we studied the following sections of the SPC of
the new drug and its comparator: side effects, contrain-
dications, warnings and precautions, drug interactions
and overdose. The side effects are presented in MedDRA
terms. The order of presentation of side effects was de-
termined according to the System Organ Class (SOC)
list of the MedDRA terminology, because this order is
used internationally.
For the impact of the drug in terms of ease of use, we
analyzed the paragraphs relating to dosage and mode of
administration present in the SPC for the new drug and
its comparator, as well as information from the evalu-
ation report [13] concerning the conditions in which
clinical trials were carried out.
We added some additional information to the items
described in our previous study [12], to provide a more
exhaustive view of the new drug. This new information
included the date of marketing authorization, the daily
cost of the drug and the target population.
For all items of the model relating to the impact of the
new drug in terms of efficacy and safety, we listed all the
possible values that the system could use for all new drugs.
Methods used for system implementation
We developed the prototype in PHP and SQL. We se-
lected five new pharmaceutical products with very dif-
ferent innovative characteristics, to illustrate the
functioning of the prototype.
For each drug, we manually collected information from
the SPC and evaluation reports, for the previously estab-
lished elements. We created a database for the storage of
all data on these products. The conclusions of the experts
were extracted from the evaluation reports. The prototype
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Bernard drug database [15] and the evaluation report.
We applied several rules when generating the inter-
face, to ensure homogeneity in terms of the representa-
tion of information. The routes of administration are
represented by pictograms. The information about the
new drug is always presented before the information
about the drug with which it is compared. When the
new drug is compared with placebo, for the safety and
ease of use aspects, only information about the new drug
is presented. The “serious drug-drug interactions”
(SDDI) are presented in gray in the impact in terms of
safety part of the interface if no SDDI has been reported.
Method of evaluation
Overall approach
Our goal was to obtain a preliminary qualitative evalu-
ation (except for the SUS score, which is semi-
quantitative), to determine whether evaluators of various
ages and medical backgrounds (i) appreciated this separ-
ation of drug information into three axes, (ii) had any
suggestions for additional information to be displayed in
the interface for each drug, (iii) appreciated the three
levels of granularity of knowledge representation, (iv)
found this prototype understandable and easy to use.
We defined several categories of physicians for this evalu-
ation. We included 10 evaluators in this evaluation (two
physicians highly specialized in the area most relevant to
the drug (a Professor of Therapeutics and a Professor of
Pharmacology at Paris 13 University), two university gen-
eral practitioners (a Professor and an Assistant Professor in
General Practice) particularly implicated in the field of ther-
apeutics in primary care, two physicians (both Professors in
Education Science carrying out research in the domain of
therapeutic education), three young, less experienced GPs
and a public health resident).
Choice of drugs
We chose five drugs recently approved in Europe and
the USA and providing real innovations with respect to
the comparator, either an active ingredient or placebo.
These five drugs were identified by the French National
Authority for Health (HAS) as being of “significant” ac-
tual benefit between 1 January 2008 and 1 April 2011.
Efient® (prasugrel), Inovelon® (rufinamide), Gylenya® (fin-
golimod), Levact® (bendamustine) and Ellaone® (ulipris-
tal), for which the improvement in actual benefit varied
from “no improvement” to “modest improvement”. The
therapeutic domain, type of treatment and type of nov-
elty of the drug also differed.
Evaluation protocol
The evaluators were provided with a printed version of
the evaluation reports for each of the five drugs. Theyalso had a printed version of the SPCs of the drugs com-
pared in the evaluation report. They had access to the
software developed in this work.
The qualitative evaluation was carried out with a spe-
cific questionnaire (see Additional file 1).
The prototype was presented to the evaluators, who
were then provided with an opportunity to use the
prototype themselves. They were then asked to complete
the questionnaire.
Physicians were also asked to complete the System Us-
ability Scale (SUS) [16], a standard algorithm for evaluat-
ing the usability of web sites. For each question, a
response is given on a scale of 1 to 5, according to the
user’s degree of satisfaction.
Results
Graphical presentation
Overall approach
We chose to represent the display consistently, using the
same stable elements and splitting the display into sev-
eral areas, as shown in Figure 1. The elements of
Figure 1B are displayed in Area 3 of Figure 1A. The
static area at the top of the page contains information
about the health problem, the exact indication for which
the drug is prescribed. The static area at the bottom of
the page contains information about the target popula-
tion, the actual benefit (AB), the improvement of actual
benefit (IAB), approval date and the comparator. These
elements are present on each page. We ensured that the
information presented in the figures remained readable,
by extracting from the display only Area 3 for some fig-
ures. The interactive area is presented as a menu. Each
element of the menu corresponds to an axis of the con-
ceptual model described in detail elsewhere [12]. We
chose to represent information according to three levels
of detail: highly synthetic, synthetic and detailed. Click-
ing on one of the buttons in the display area reveals the
second level of detail. The hypertext link area provides
access to the most detailed level, corresponding to ex-
cerpts from the evaluation report [13] and SPC.
Description of the interface showing highly synthetic
information
Figure 2 shows an overview of the main features of the
new drug Efient® (prasugrel), 10 mg, administered together
with acetylsalicylic acid for the prevention of atherothrom-
botic events in patients with acute coronary syndrome
undergoing primary or delayed percutaneous coronary
intervention (PCI). This drug was authorized for market
release on February 25, 2009. The actual benefit of Efient®
was rated “significant.” However, this drug provided no
improvement over the available therapeutic arsenal (level
5 of the French classification). Efient® (prasugrel, 10 mg) is
compared to Plavix® (clopidogrel, 75 mg).
Figure 1 Illustration of the organization of information in the prototype. (a) – Area 1 includes the trade name of the drug, its dose and form, and
its indication. Area 2 represents the axes of the conceptual model in the form of a menu containing highly synthetic information; Area 3 shows the
synthetic information; Area 4 includes information about the target population, actual benefit, improvement in actual benefit, approval date and
comparator. (b) – The three levels of information detail (I – highly synthetic, II – synthetic, III – detailed). Area 1, Area 4 and Area 2 corresponding to
Level I from (b) are always present. The level II of granularity is shown in Area 3 when the physician chooses a topic from the menu. From level II, the
user can obtain level III of detail by clicking on the hypertext link.
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Novelty of the new drug The user must click on the
corresponding item in the menu to find out what is new
about the pharmaceutical product. For example, the
novelty of Efient® lies in the presence of a new molecule,
prasugrel hydrochloride. This is illustrated in Figure 3.
Other drug options with the same indication The
user must click on the corresponding item in the menu
to find out what other options are available for the same
indication.
We generated a table, in which products are grouped
according to pharmacotherapeutic group and mechan-
ism of action and the route of administration is shown,
to provide a representation of all drugs with the same
indication. Pictograms are used to represent the route of
administration of the product to facilitate comparisons
between drugs.
Figure 4 shows all the drugs prescribed for the same
indication. Daily costs of the drug are presented if avail-
able. Unfortunately, this value cannot always be calcu-
lated, because the dose may depend on the weight or
body surface area of the patient, for example.
Impact of the new drug in terms of efficacy We used
tables to visualize the impact of the drug in terms ofefficacy, safety and ease of use. For comparisons of the
efficacy of the new drug and its comparator, the table in-
cludes the values of endpoints measured in clinical trials,
the endpoints in a given trial being identical for the two
drugs compared, and the probability value p quantifying
the statistical significance of the type of effect. In cases
in which this p value is less than 0.05, the existence of a
significant difference is indicated in green. The thick line
divides the numerical values obtained in clinical trials
from the experts’ conclusions, which are provided at the
bottom of the table and are taken from the evaluation
report. The impact of Efient® in terms of efficacy is
shown in Figure 5.
Impact of the new drug in terms of safety The use of
the attribute “color” in the representation of the impact
of the drug on safety makes it possible to represent vari-
ous types of information within a single cell. Figure 6
shows the possible values for the frequency of serious
adverse reactions, serious drug-drug interactions, con-
traindications and the risk of overdose.
We took into account only “absolute” contraindica-
tions for the new drug and the comparator. Similarly, for
drug-drug interactions, we considered only associations
that are contraindicated. Figure 7 shows the impact of
the drug Efient® on safety.
Figure 2 The highly synthetic level of the interface for Efient®.
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from clinical trials, are shown at the top of the table.
The conclusions of the experts, taken from the evalu-
ation report, are shown at the bottom of the table, below
the thick line.
Impact of the new drug in terms of ease of use The
information for each drug was derived from the descrip-
tion of the clinical study presented in the evaluation re-
port [13] and the “Dosage and Administration” section
of the SPC. We represented the impact of the new drug
on ease of use, by considering the various items relating
to this subaxis in our model. However, we display only
information that is actually informative for the reader.
For example, in Figure 8, for the new drug Efient®, we do
not take into account items that are not relevant for the
two drugs (e.g.: duration of administration for tablets,
duration of an anticoagulant treatment, convenience of
administration and adjustment of dose) or items not
mentioned in the sources used (e.g.: complexity of treat-
ment monitoring). There is no difference in ease of use
between prasugrel and clopidogrel, both of which are
taken once daily in tablet form.Description of the interface showing detailed information
Detailed information about efficacy
The doctor can access additional information about effi-
cacy by clicking on “More details”. This brings up ex-
cerpts from the SPC and/or the evaluation report.
When the user clicks on the hypertext link “More de-
tails” in Area 2, the detailed information about efficacy
is displayed in a new window. For Efient®, the text is-
sued from the efficacy subsection of the evaluation re-
port of the Transparency Commission (22 July 2009) is
the following:
“The combination of prasugrel (EFIENT) + aspirin
was associated with a significant reduction in
ischemic events, including stent thrombosis,
compared to the combination of clopidogrel
(PLAVIX) + aspirin after a median follow-up of 15
months treatment. The difference in risk (absolute
benefit) was 2.1% (9.4% versus 11.5% in the overall
population, p < 0.001) in favour of the prasugrel
group. This effect was essentially due to a reduction
in the risk of experiencing a non-fatal myocardial
infarction (9.1% in the clopidogrel group and 7.0% in
Figure 3 Representation of the novelty of Efient® (the synthetic level, Area 3). When the user clicks on the topic “What is new in this pharmaceutical
product?” in Area 2, the feature(s) of novelty of this new drug is (are) displayed in Area 3.
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the two groups was observed in mortality (from any
cause or from a cardiovascular cause).”
Detailed information about safety
As for efficacy, the physician can obtain additional infor-
mation about safety, by clicking on the hypertext link
“More details” in Area 2.
For Efient®, we give here three texts issued from the
safety subsection of the evaluation report of the Trans-
parency Commission (22 July 2009):
a) For serious adverse reactions
“Premature cessation because of a bleeding event was
more frequent in the prasugrel group (2.5%) than in
the clopidogrel group (1.4%). A higher rate of
bleeding was observed in the prasugrel group: major
bleeding not related to CABG (2.17% in the prasugrel
group and 1.65% in the clopidogrel group, p=0.029);potentially life-threatening bleedings (1.26% in the
prasugrel group versus 0.83% in the clopidogrel
group, 0=0.015) including fatal bleedings (0.31%
versus 0.07%, p=0.002).
In patients with a history of stroke or TIA the
risk-benefit ratio of prasugrel (EFIENT) was
unfavourable: treatment with EFIENT is
contraindicated.”b) For contraindications
Both drugs are contraindicated in patients
with pathological bleeding, as well as severe
hepatic impairment.
Contrary to clopidogrel, prasugrel is
contraindicated in persons with known
hypersensitivity to castor oil.
For people with a history of transient ischemic attack
and stroke, prasugrel is contraindicated, while
clopidogrel is not recommended.
Figure 4 Screenshot showing all the drugs with the same indication as Efient® (prasugrel) (the synthetic level, Area 3). When the user clicks on
the topic “What other options are in the same indication?” in Area 2, the table with all the drugs sharing the same indication is displayed in
Area 3.
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“An overdose of prasugrel and clopidogrel may cause
prolonged bleeding time and subsequent bleeding
complications. There are no data on the neutralization
or pharmacological effect of prasugrel or clopidogrel,
but if a prompt correction of prolonged bleeding time is
required, a platelet transfusion and/or other blood
products may be considered.”Evaluation of the prototype
All the physicians appreciated the representation of in-
formation according to three levels of granularity: highly
synthetic, synthetic and detailed.Eight physicians agreed with the choice of three axes
for the description of pharmaceutical innovation (con-
text, novelty and impact). A professor specializing in
general practice suggested that more detail could be pro-
vided for the novelty axis, with a judgment on the results
of completed trials, particularly when the novelty con-
cerns a new molecule. A professor of education sciences
suggested that the name “ease of use” was not ideal for
the last axis, but he proposed no alternative formulation.
Six of the 10 physicians considered the two synthetic
levels of granularity of the description sufficient for the
rapid construction of an opinion concerning the drug.
The others felt that all three levels of granularity were
important for forming an opinion.
Figure 5 Screen shot showing the impact of Efient® on efficacy (the synthetic level, Area 3). When the user clicks on the topic “What is the
impact of drug on efficacy?” in Area 2, a comparison of the efficacy of the two drugs is displayed in Area 3. The thick line separates the numerical
values obtained in clinical trial from the experts’ conclusions coming from the evaluation report, which are shown at the bottom of the table.
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possible occurrence and frequency of serious adverse re-
actions easy to understand. The professor of general
practice felt that it was important to specify the fre-
quency of serious adverse reactions by giving the per-
centage recorded during clinical trials.
All doctors found the mode of comparison of contra-
indications and risks of overdose easy to understand.Figure 6 Ways of representing safety characteristics: serious adverse reactioEight physicians felt that the comparison of the efficacy
of the new drug with that of its comparator was easy to
understand. Eight physicians felt that it was easy to de-
termine whether there were other drugs in the same
therapeutic class for the same indication.
Some evaluators suggested adding information about
the drug, such as the detailed dosage schedule and pre-
cautions for use (the professor of pharmacology and ans, contraindications, serious drug-drug interactions, risk of overdose.
Figure 7 Screen shot showing the impact of Efient® on safety (the synthetic level, Area 3). When the user clicks on the topic “What is the impact
of drug on safety?” in Area 2, a comparison of the safety of the two drugs is displayed in Area 3.
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Figure 8 Screen shot showing the impact of Efient® on ease of use (the synthetic level, Area 3). When the user clicks on the topic “What is the
impact of drug on ease of use?” in Area 2, a comparison of the ease of use of the two drugs is displayed in Area 3.
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(the professor of therapeutics), and the rate of reimburse-
ment by the social security system (public health resident).
The time required to form an opinion about the po-
tential value of a new drug was estimated at three mi-
nutes by three evaluators, at five minutes by two and at
five to ten minutes by two evaluators.
One evaluator felt that it was impossible to get a clear
idea from the sources used (SPC and evaluation report).
He felt that there was a problem concerning the reliabil-
ity of information. The mean score attributed by the 10
physicians was high, at 82, corresponding to a “good”
user interface.
Discussion
On the basis of these findings, we propose the selection,
grouping and presentation of types of knowledge relating
to pharmaceutical innovations, to provide physicians
with easily accessible, objective information about new
drugs. The design of the prototype presented here was
based on modeling of the main elements of pharmaceut-
ical innovations identified in our recent study. Our ob-
jective was to provide physicians (mostly GPs) with a
tool enabling them to decide rapidly whether a new drug
is of potential interest for use in their practices.
We have taken into account the limitations to the
amount of information a user can examine and process
at a given moment due to his or her cognitive and per-
ceptual abilities [17]. Physicians thus require an overall
idea of the utility of the new drug, based on an overview
of its main properties. We therefore propose three levels
of granularity, from highly synthetic to detailed.
It has been shown [18] that standardized and consist-
ent interfaces are required for users to be able to master
their use without special training. For this reason, we
chose to represent the interface with stable elements, to
avoid the need for learning.
We used graphical representation in the form of picto-
grams, because it has been shown that users prefer
graphical interfaces, which facilitate learning to a greater
extent than purely textual interfaces [19].
We considered only the texts available from the na-
tional drug agencies at the time of market release. Thesetexts are restricted to the evaluation reports written by
the experts working for these agencies and the texts of
the SPC for the new drug and the drugs with which it
is compared. We did not take scientific articles report-
ing the results of the trials conducted for evaluation of
the new drug into account, because we considered the
reading of these texts to be too time-consuming
for physicians.
At the most detailed level, our prototype provides ex-
cerpts of the evaluation reports written for the French
National Authority for Health (HAS). We could also
have considered evaluation reports prepared in other
countries, which would be particularly interesting in
cases in which opinions differ. We plan to tackle this as-
pect in future studies.
We used the results of clinical trials to describe the im-
pact of the drug in terms of efficacy. The comparator was
identified from clinical trials. For comparisons of the safety
of the new drug with its comparator, we restricted the ana-
lysis to serious adverse events, serious drug-drug interac-
tions, contraindications and the risk of overdose. This
made it possible to focus on the most important aspects
of the pharmaceutical innovation, rather than providing
doctors with too much information, which might deter
them from reading. As we had mentioned in our previous
work [12], we compare the new drug to existing drugs
with exactly the same indication. The therapeutic arsenal
is identified for this indication in evaluation reports. If the
drug is approved for many indications, a separate repre-
sentation is made for each indication.
We show only the serious adverse reactions defined
precisely in the study [20] on the basis of explicit cri-
teria. This choice facilitates the selection of adverse reac-
tions to be included in the system for each new drug.
Our visual approach, combining color and texture,
seems particularly appropriate for the comparison of
side effects, which may occur with both new and old
drugs, because a side effect may be present or absent
and, if present, its frequency may vary. We did not take
color blindness (an inability to distinguish between red
and green) into account. However, when the user places
the mouse over the colored area, a text providing a de-
scription is displayed.
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[21], who proposed data visualization methods for the
representation of potential adverse drug events in pa-
tients on multiple medications.
Our interface was designed to compare only two drugs
at a time, but this is not a major limitation, because
(i) most clinical trials compare no more than two drugs,
(ii) for safety evaluations, our prototype could easily be
adapted for the comparison of more than two drugs, by
adding additional columns if similar types of data are
available for all the drugs.
Our method of presenting information draws attention
to the drugs that are the first to be released for a given in-
dication. If there are no other drugs for the indication con-
cerned, then the drug may be considered truly innovative.
In such cases, the information is less rich for safety and
ease-of-use representation, because there is no compara-
tor. Similarly, if the comparator is a placebo, there are no
comparative data concerning safety and ease of use.
The evaluation was carried out by GPs and highly
qualified professionals specializing in particular areas,
with different skills, to provide us with a diverse range
of opinions concerning the various elements and the
classification of items. We now plan to ask GPs to carry
out a more specific evaluation, in which we will compare
the time required for a GP to answer questions about a
new drug correctly with the full-text documents and
with the software.
The information visualization procedure provided by
this prototype software was much appreciated by the phy-
sicians participating in its evaluation. None of these physi-
cians felt that any internationally important information
was missing and should be added, but the addition of
nation-specific information should be considered if this
prototype is to be adapted for use in other countries. The
decision to present information at multiple levels of detail
was also particularly appreciated by the evaluators, who
found the prototype easy to understand and to use.
More detailed information could have been provided
on the first screen. However, we chose to provide only
the information permitting the physician to determine
very quickly whether the new drug was likely to be of
any value for his or her own practice.
It is also easy to add new drugs to this system. Infor-
mation can be introduced into the system by a pharma-
cist without programming skills. For each drug, it takes
between a half day and two days to add the information
required, depending on the number of drugs in the
therapeutic arsenal and the number of adverse reactions
to the new drug and its comparator.
Conclusion
Overall, we believe that this work can serve as a tem-
plate for efforts to provide objective information aboutnew drugs from health agencies, training organizations,
medical journals and the pharmaceutical industry, which
might be interested in rationalizing the information pro-
vided to potential prescribers of new products.
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